Outlook Therapeutics remains a high-risk, pre-commercial biotechnology entity characterized by sporadic revenue streams and a persistent reliance on external financing to fund clinical development. The company's financial position is heavily strained, with a n...
Price trend, volume and key moving averages
Trailing total returns as of 9/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.14-75.0% vs -$0.08 | $9,000-99.1% vs $966,667 |
Q2 2026 May 15, 2026 | -$0.16-33.3% vs -$0.12 | $128,000-97.1% vs $4M |
Q1 2026 Feb 17, 2026 | -$0.22-29.4% vs -$0.17 | $1M-138.4% vs $3M |
Q4 2025 Dec 19, 2025 | -$0.22+4.3% vs -$0.23 | $100,000-101.7% vs $6M |
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure
Video webcast now available here
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Oncobiologics (NASDAQ: OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States. President and Chief Executive Officer Bob Jahr called the approval
Benchmark OTLK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Outlook Therapeutics, Inc. (OTLK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.64 | $16.32M | -0.36 | — | -4416.22% | — | — | |
| $3.71 | $405.11M | -1.85 | — | — | -5.76% | — | |
| $4.36 | $96.26M | -0.66 | -72.22% | — | — | — | |
| $14.77 | $1.24B | -4.37 | — | — | -159.32% | — | |
| $123.96 | $9.13B | -21.19 | — | — | -42.78% | — | |
| $810.31 | $83.48B | 19.54 | 0.99% | 27.86% | 18.49% | — |
Outlook Therapeutics, Inc. (OTLK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Outlook Therapeutics, Inc. (OTLK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 27, 2026·SEC
Aug 14, 2026·SEC
Aug 14, 2026·SEC
Dec 19, 2025·SEC
Get notified when OTLK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Outlook Therapeutics, Inc. (OTLK) stock FAQ — growth, dividends, profitability & financials explained
Outlook Therapeutics, Inc. (OTLK) reported $-1.2M in revenue for fiscal year 2025. This represents a 113% decrease from $9.1M in 2014.
Outlook Therapeutics, Inc. (OTLK) reported a net loss of $61.1M for fiscal year 2025.
Outlook Therapeutics, Inc. (OTLK) had negative free cash flow of $57.1M in fiscal year 2025, likely due to heavy capital investments.
